Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases

NCT07413939 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT07413939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07413939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part, Seamless, Multicenter, Randomized, Open-label, Adaptive Phase II/III Study of the Blood-brain Barrier Penetrant RO7771950 Versus Tucatinib, Both in Combination With Trastuzumab and Capecitabine, in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer, With or Without Central Nervous System Metastases
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 21, 2026
Completion date
September 29, 2032
Enrollment
650 (estimated)
Sites
206

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer